Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia

• Published in: British journal of haematology Vol. 202; no. 4; pp. 856 - 865
• Main Authors: Huo, Wen‐Xuan, Wen, Qi, Zhang, Xiao‐Hui, Xu, Lan‐Ping, Wang, Yu, Yan, Chen‐Hua, Chen, Huan, Chen, Yu‐Hong, Han, Wei, Wang, Feng‐Rong, Wang, Jing‐Zhi, Huang, Xiao‐Jun, Mo, Xiao‐Dong
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.08.2023
• Subjects: acute myeloid leukaemia; Acute myeloid leukemia; adolescent and young adults; allogeneic haematopoietic stem cell transplantation; Comorbidity; haploidentical; Hematology; Hematopoietic stem cells; Leukemia; Mortality; Remission; Stem cell transplantation; Young adults; adolescent and young adults; haploidentical; acute myeloid leukaemia; allogeneic haematopoietic stem cell transplantation
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.18937

Summary We aimed to identify the efficacy of haploidentical related donor (HID) haematopoietic stem cell transplantation (HSCT) in adolescent and young adults (AYAs) with acute myeloid leukaemia (AML) in a large cohort. Consecutive AML AYAs (15–39 years old, n = 599) receiving HID HSCT in complete remission (CR) were included. The 3‐year cumulative incidence of measurable residual disease occurrence, relapse and non‐relapse mortality after HID HSCT was 28.6% (95% CI: 25.0–32.2), 11.6% (95% CI: 9.0–14.2) and 6.7% (95% CI: 4.7–8.7) respectively. The 3‐year probability of event‐free survival, leukaemia‐free survival (LFS) and overall survival (OS) after HID HSCT was 60.7% (95% CI: 56.9–64.8), 81.7% (95% CI: 78.7–84.9) and 85.6% (95% CI: 82.8–88.4) respectively. In multivariable analysis, AML risk category at diagnosis and comorbidity burdens before HID HSCT were independently associated with LFS and OS. Compared to the older adults (≥ 40 years, n = 355) with AML receiving HID HSCT in CR during the same time period, AYAs have a lower incidence of non‐relapse mortality and higher probabilities of LFS and OS. Thus, we firstly confirmed the safety and efficacy of HID HSCT in AYAs with AML‐CR. The 3‐year probabolities of overall survival after haploidentical related donor haematopoitic stem cell transplantation according to (A) favourable‐, intermidiate‐ and poor‐risk acute myeloid leukaemia category at diagnosis and (B) low‐ intermidiate‐ and high‐risk haematopoietic stem cell transplantation‐specific comorbidity index scores before allo‐ haematopoietic stem cell transplantation.